Disease · MONDO_0005192

exocrine pancreatic carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. exocrine pancreatic carcinoma. Diseases, record MONDO_0005192. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005192

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: exocrine pancreatic carcinoma; Open Targets
Open Targets ID: MONDO_0005192; Open Targets
Other names: carcinoma of exocrine pancreas, carcinoma of pancreas, carcinoma of the pancreas, exocrine pancreas carcinoma, pancreas carcinoma, pancreatic cancer (not islets), pancreatic carcinoma; Open Targets
Disease Ontology: DOID:4905; Disease Ontology
NCI Thesaurus: C3850; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 253 drugs, from DailyMed; Open Targets

Drugs253

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
GEMCITABINE HYDROCHLORIDE	CHEMBL1637	Small molecule	Approval	DailyMed	33	29	29	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	237	237	237	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	80	80	67	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	75	75	56	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	68	68	56	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	62	62	62	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	43	43	35	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	30	30	29	Drugs and targets
ERLOTINIB	CHEMBL553	Small molecule	Phase 3	ClinicalTrials.gov	30	30	30	Drugs and targets
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Phase 3	ClinicalTrials.gov	28	28	20	Drugs and targets

1 to 10 of 253

See all 253 drugs

Targets333

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	15	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	12	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	12	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	11	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	11	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDCD1	Programmed cell death protein 1	10	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
EGFR	Epidermal growth factor receptor	9	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	7	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5156	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	6	Macrophage colony stimulating factor receptor antagonist; Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	6	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 3	https://conductscience.org/library/genes/2322	Drugs and targets

1 to 10 of 333

See all 333 targets

Trials468

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03797326	Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)	Phase 2	611	2025-11-17	Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer	LENVATINIB, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01214720	A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer	Phase 3	607	2014-08-13	Pancreatic Cancer	BEVACIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00652366	A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer	Phase 2	467	2015-02-11	Pancreatic Cancer	ERLOTINIB, GEMCITABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03184870	A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors	Phase 1/2	332	2025-10-09	Colorectal Cancer, Pancreatic Cancer	BMS-813160, FLUOROURACIL, GEMCITABINE, IRINOTECAN, LEUCOVORIN CALCIUM, NIVOLUMAB, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00276744	Individualized Drug Treatment for Treating Patients With Pancreatic Cancer	Phase 2	249	2018-08-27	Pancreatic Cancer	BORTEZOMIB, CAPECITABINE, CETUXIMAB, DOCETAXEL, ERLOTINIB, GEMCITABINE, IRINOTECAN, MITOMYCIN, SIROLIMUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT04332653	NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors	Phase 1/2	215	2026-02-09	Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer	EFINEPTAKIN ALFA, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00674973	A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer	Phase 2	207	2016-04-26	Pancreatic Cancer	ERLOTINIB	Its record names the disease	ClinicalTrials.gov
NCT01395017	Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer	Phase 2	202	2015-03-17	Pancreatic Cancer	DASATINIB ANHYDROUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT01373164	A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer	Phase 1/2	170	2018-05-16	Neoplasms, Neoplasm Metastasis, Pancreatic Cancer	GALUNISERTIB, GEMCITABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00570713	An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer	Phase 2	155	2012-03-27	Pancreatic Cancer	AMATUXIMAB, GEMCITABINE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 468

See all 468 trials

Comparisons in its trials73

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Bevacizumab + Gemcitabine + Erlotinib vs Placebo + Gemcitabine + Erlotinib: serious adverse events	139 of 297	119 of 286	583	NCT01214720	Trial comparisons
Erlotinib vs Placebo: Number of Participants With Adverse Events (AEs)	90 of 104	71 of 103	207	NCT00674973	Trial comparisons
Erlotinib vs Placebo: serious adverse events	21 of 104	11 of 103	207	NCT00674973	Trial comparisons
Dasatinib + GEM vs Placebo + GEM: serious adverse events	53 of 98	48 of 101	199	NCT01395017	Trial comparisons
Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2: Number of Participants Who Died at 6 Months	69 of 115	8 of 38	153	NCT00461708	Trial comparisons
Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2: Number of Participants With Disease Progression or Death	110 of 115	33 of 38	153	NCT00461708	Trial comparisons
Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2: Number of Participants Who Died During the Study	102 of 115	27 of 38	153	NCT00461708	Trial comparisons
Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2: serious adverse events	58 of 115	14 of 38	153	NCT00461708	Trial comparisons
MORAb-009 Plus Gemcitabine ('MORAb-009') vs Placebo Plus Gemcitabine ('Placebo'): serious adverse events	49 of 73	54 of 75	148	NCT00570713	Trial comparisons
Arm A (Nab-Paclitaxel + Gemcitabine) vs Arm B (Gemcitabine): deaths from any cause	5 of 72	11 of 74	146	NCT02106884	Trial comparisons

1 to 10 of 73

See all 73 comparisons in its trials

Papers from its trials223

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41747221	RESULT	1	PubMed
40762544	RESULT	1	PubMed
39846249	RESULT	1	PubMed
39031824	RESULT	1	PubMed
38718741	RESULT	1	PubMed
35399603	RESULT	1	PubMed
32067509	RESULT	1	PubMed
31894292	RESULT	1	PubMed
31882719	RESULT	1	PubMed
31831767	RESULT	1	PubMed

1 to 10 of 223

See all 223 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005192

GET https://conductscience.org/api/diseases/v1/MONDO_0005192/drugs?page=2

API reference For AI assistants